Castrate resistant prostate cancer: New therapeutic approaches
Today Dr. Martin Gleave of the Vancouver Prostate Centre in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP) during the 24th Annual Congress of the European Association of Urology in Stockholm, Sweden. "If we look at the way kidney cancer treatment has changed over recent years we see a glimpse of the future", says Dr Gleave, "Targeted therapies may become available".
Recent studies indicate that tumour cells can develop an ability to synthesise enzymes to produce their own androgens for androgen receptor (AR) activation after castration.
CRPC tumours are not uniformly hormone resistant and may remain sensitive to therapies directed against the ARs. Dr Gleave: "Several new classes of AR-targeting agents are now in clinical development, including the 2nd generation anti-androgen MDV3100, abiraterone, and Hsp27 (OGX-427)".
The growth of new blood vessels, angiogenesis, plays an essential role in prostate cancer development and metastasis. "Among the various angiogenic targets implicated in tumour angiogenesis, vascular endothelial growth factor (VEGF), a potent angiogenic growth factor, and its receptor have evoked a lot of interest," according to Dr Gleave. Bevacizumab targets VEGF and is a promising angiogenesis inhibitor in this indication. Other agents in late stage trials include sunitinib.
Clusterin is a stress-induced, multi-functional, molecular chaperone. A novel, phase I pre-prostatectomy trial defined the optimal biologically dose and toxicity parameters of OGX-011 with maximal knockdown of clusterin in prostate and lymph node tissues at the 640 mg dose level. A phase II study includes 81 men with CRPC to receive either docetaxel and OGX-11 (n=40) or docetaxel alone (n=41).
"All in all, we need to move forward with the momentum and continue to let biology guide treatment developments", said Gleave, who also expressed his gratitude for being invited to speak at the 24th Annual EAU Congress.
Source: European Association of Urology
Articles on the same topic
- US trial shows no early mortality benefit from annual prostate cancer screeningWed, 18 Mar 2009, 20:50:59 UTC
- PSA screening cuts deaths by 20 percentWed, 18 Mar 2009, 16:46:45 UTC
Other sources
- When early screening carries risksfrom LA Times - HealthFri, 27 Mar 2009, 3:42:16 UTC
- PSA Screening Cuts Deaths By 20 Percentfrom Science DailyTue, 24 Mar 2009, 15:35:58 UTC
- No Early Mortality Benefit From Annual Prostate Cancer Screening, U.S. Study Showsfrom Science DailyTue, 24 Mar 2009, 15:35:56 UTC
- Well: Screen or Not? What Those Prostate Studies Meanfrom NY Times ScienceTue, 24 Mar 2009, 0:00:09 UTC
- When early screening carries risksfrom LA Times - HealthSat, 21 Mar 2009, 0:14:37 UTC
- Studies cast doubt on prostate cancer screeningsfrom LA Times - HealthThu, 19 Mar 2009, 7:22:30 UTC
- Prostate screening not reducing deathsfrom UPIThu, 19 Mar 2009, 4:07:39 UTC
- Prostate cancer screenings provide little benefit, studies showfrom LA Times - ScienceThu, 19 Mar 2009, 0:56:11 UTC
- PSA screening cuts deaths by 20 percentfrom PhysorgWed, 18 Mar 2009, 22:21:23 UTC
- Prostate Cancer Screening Exams Not Necessary for Some Men (w/Video)from PhysorgWed, 18 Mar 2009, 21:08:16 UTC
- Studies show small benefit or none at all to prostate-cancer screeningfrom CBC: HealthWed, 18 Mar 2009, 20:07:29 UTC
- Studies don't end prostate cancer test controversyfrom PhysorgWed, 18 Mar 2009, 16:43:52 UTC
- Prostate Cancer Screening Found to Save Few, if Any, Livesfrom NY Times HealthWed, 18 Mar 2009, 16:28:07 UTC
- Folic Acid Supplements Linked To Higher Risk Of Prostate Cancer, Study Showsfrom Science DailyWed, 18 Mar 2009, 1:28:33 UTC